Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dannon Launches New Activia Product, DanActive, Forms Partnerships

This article was originally published in The Tan Sheet

Executive Summary

Dannon will launch Activia Light nonfat yogurt in the U.S. following the successful introduction of the original version of the product, the firm announced Jan. 22

You may also be interested in...



Sales & Earnings In Brief

Nutrition 21: Total revenues for the Purchase, N.Y.-based firm's fiscal 2007 Q2 (ended Dec. 31, 2006) were $9.4 mil. compared to $2.1 mil. for the prior-year period. "We are beginning to benefit from the synergies we expected from our Iceland Health acquisition," Nutrition 21 CEO Paul Intlekofer says in a Feb. 13 release. Nutrition 21 announced in August 2006 its plan to acquire Iceland Health (1"The Tan Sheet," Aug. 21, 2006, p. 5). Intlekofer also says the firm is on schedule to begin national distribution of both Iceland Health Maximum Strength Omega-3 and Iceland Health Joint Relief products between March and May at major food, drug and mass retailers. "By the end of our fiscal year on June 30, we expect to have five branded product lines in national distribution that address pre-diabetes, diabetes, cardiovascular health, arthritis/joint health and HIV," Intlekofer says...

Sales & Earnings In Brief

Nutrition 21: Total revenues for the Purchase, N.Y.-based firm's fiscal 2007 Q2 (ended Dec. 31, 2006) were $9.4 mil. compared to $2.1 mil. for the prior-year period. "We are beginning to benefit from the synergies we expected from our Iceland Health acquisition," Nutrition 21 CEO Paul Intlekofer says in a Feb. 13 release. Nutrition 21 announced in August 2006 its plan to acquire Iceland Health (1"The Tan Sheet," Aug. 21, 2006, p. 5). Intlekofer also says the firm is on schedule to begin national distribution of both Iceland Health Maximum Strength Omega-3 and Iceland Health Joint Relief products between March and May at major food, drug and mass retailers. "By the end of our fiscal year on June 30, we expect to have five branded product lines in national distribution that address pre-diabetes, diabetes, cardiovascular health, arthritis/joint health and HIV," Intlekofer says...

Sales & Earnings In Brief

Nutrition 21: Total revenues for the Purchase, N.Y.-based firm's fiscal 2007 Q2 (ended Dec. 31, 2006) were $9.4 mil. compared to $2.1 mil. for the prior-year period. "We are beginning to benefit from the synergies we expected from our Iceland Health acquisition," Nutrition 21 CEO Paul Intlekofer says in a Feb. 13 release. Nutrition 21 announced in August 2006 its plan to acquire Iceland Health (1"The Tan Sheet," Aug. 21, 2006, p. 5). Intlekofer also says the firm is on schedule to begin national distribution of both Iceland Health Maximum Strength Omega-3 and Iceland Health Joint Relief products between March and May at major food, drug and mass retailers. "By the end of our fiscal year on June 30, we expect to have five branded product lines in national distribution that address pre-diabetes, diabetes, cardiovascular health, arthritis/joint health and HIV," Intlekofer says...

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel